Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion type Assertion NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_head.
- NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_provenance.
- NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion evidence source_evidence_literature NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_provenance.
- NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion SIO_000772 24486524 NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_provenance.
- NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion wasDerivedFrom befree-2016 NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_provenance.
- NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion wasGeneratedBy ECO_0000203 NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_provenance.